ORKA

Business Context and Reporting Period

Company: Nuvelo, Inc. (formerly Hyseq, Inc.)
Filing Type: Form 10-K
Period Ended: December 31, 2002
Business Overview: Nuvelo is a biopharmaceutical company focused on the discovery and development of novel biotherapeutics. The company operates two reportable segments: Nuvelo (therapeutic drugs) and Callida Genomics (sequencing-by-hybridization technology).
Strategic Shift: Following a merger with Variagenics, Inc. on January 31, 2003, the company is pivoting to focus resources on its lead candidate, alfimeprase, while monetizing non-core assets like its microarray and pharmacogenomic businesses.

Key Financial Metrics

Liquidity Update: As of the merger date (January 31, 2003), the combined entity held approximately $53.2 million in cash.

Material Changes vs. Prior Period

• Revenue Growth: Contract revenues increased 7.5% to $26.4 million, driven primarily by amortization of deferred license revenue from Affymetrix ($2.7 million) and continued gene screening services from BASF ($21.9 million).
• Increased Losses: Net loss widened by $8.5 million to $45.0 million. This was largely due to a $10.0 million non-cash charge for warrants issued to Amgen for the alfimeprase collaboration and $2.1 million in restructuring charges.
• Operating Expenses: Total operating expenses rose 15.6% to $70.4 million. Research and Development (R&D) expenses increased by $3.7 million, while General and Administrative (G&A) expenses rose $4.7 million, partly due to a $6.1 million expense for early lease termination.
• Cash Position: Cash and cash equivalents decreased by $10.1 million to $2.2 million, reflecting $31.3 million in cash used for operating activities and $2.1 million in capital expenditures, partially offset by $14.3 million from a private stock placement and $10.0 million drawn from a line of credit.

Guidance, Outlook, and Risks

Outlook and Management Commentary

• Alfimeprase Progress: The lead candidate, alfimeprase (a thrombolytic), successfully completed Phase I trials in Q1 2003 with no drug-related adverse events. The company plans to initiate Phase II trials for peripheral arterial occlusion (PAO) and catheter occlusion in the first half of 2003.
• Capital Runway: Management expects the cash resulting from the Variagenics merger to fund operations through 2004.
• Revenue Expectations: Revenues are anticipated to decrease in 2003 due to the completion of the BASF collaboration in January 2003.

Risks and Contingencies

• Delisting Risk: The company received a deficiency notice from Nasdaq for trading below $1.00 per share for 30 consecutive days. Failure to regain compliance by July 28, 2003, could result in delisting.
• Liquidity Constraints: The company has a history of net losses and requires additional capital. Financing may be unavailable or dilutive.
• Legal Proceedings: The company is defending a securities class action lawsuit inherited from Variagenics regarding alleged underwriter commissions in Variagenics' 2000 IPO.
• Regulatory Approval: No products are currently approved for sale. Success depends on obtaining FDA approval for alfimeprase and other candidates, which is uncertain and costly.

Investor Verification Checklist

• Merger Integration: Verify the actual cash balance post-merger ($53.2 million reported) and the timeline for funding operations through 2004.
• Nasdaq Compliance: Monitor stock price performance to ensure compliance with the $1.00 minimum bid requirement to avoid delisting.
• Alfimeprase Clinical Data: Review results of the upcoming Phase II trials for PAO and catheter occlusion scheduled for 2003.
• Revenue Sustainability: Assess the impact of the terminated BASF collaboration on future revenue streams and the success of monetizing non-core assets.
• Legal Exposure: Track the status of the Variagenics securities class action lawsuit and potential settlement costs.